| Glenmark Pharmaceuticals Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 532296 |
NSE Symbol : GLENMARK |
P/E(TTM) : 37.18 |
|
ISIN Demat : INE935A01035 |
Div & Yield% : 0.13 |
EPS(TTM) : 52.14 |
|
Book Value(₹) : 848.31 |
Market Cap(₹Cr) : 54,700.39 |
Face Value(₹) : 1.00 |
| Particulars | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | - | - | - | - | - |
| Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Sales | 9,226.41 | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 |
| Other Income | 356.37 | 6,238.36 | 985.94 | 1,044.96 | 470.13 |
| Stock Adjustments | -44.48 | 103.07 | 31.37 | 16.13 | -5.24 |
| Total Income | 9,538.30 | 14,232.55 | 9,237.97 | 9,202.67 | 8,032.82 |
| EXPENDITURE : | |||||
| Raw Materials | 3,154.65 | 3,313.19 | 3,427.07 | 3,425.06 | 2,944.53 |
| Power and Fuel Cost | 114.62 | 104.92 | 95.09 | 91.34 | 80.49 |
| Other Manufacturing Expenses | 372.36 | 375.32 | 304.66 | 347.04 | 267.26 |
| Selling and Administration Expenses | 1,305.30 | 1,199.17 | 1,246.10 | 1,062.89 | 914.37 |
| Miscellaneous Expenses | 566.49 | 325.15 | 855.71 | 349.97 | 358.30 |
| Employee Benefit Expenses | 1,603.50 | 1,434.78 | 1,346.51 | 1,193.20 | 1,107.40 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 2,421.38 | 7,480.02 | 1,962.84 | 2,733.18 | 2,360.47 |
| Interest | 48.73 | 277.11 | 206.82 | 236.04 | 265.90 |
| Gross Profit | 2,372.65 | 7,202.91 | 1,756.02 | 2,497.14 | 2,094.57 |
| Depreciation | 218.63 | 202.16 | 184.15 | 159.70 | 150.82 |
| Profit Before Tax | 2,154.02 | 7,000.75 | 1,571.87 | 2,337.44 | 1,943.75 |
| Current Tax | 316.09 | 1,049.99 | 386.93 | 411.08 | 343.62 |
| Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | 227.58 | 783.46 | -23.83 | -71.42 | -49.31 |
| Reported Net Profit | 1,610.35 | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 |
| Extraordinary Items | -133.98 | 3,742.26 | -369.56 | 354.02 | 59.87 |
| Adjusted Net Profit | 1,744.33 | 1,425.03 | 1,578.33 | 1,643.77 | 1,589.58 |
| Adjustment below Net Profit | -6.47 | -4.76 | 0.63 | 1.61 | 2.48 |
| Profit/Loss Balance carried down | 21,088.13 | 16,002.82 | 14,863.96 | 12,921.86 | 11,340.47 |
| Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Appropriations | 110.87 | 77.22 | 70.54 | 57.30 | 70.54 |
| P & L Balance carried down | 22,581.15 | 21,088.13 | 16,002.82 | 14,863.96 | 12,921.86 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity Dividend (%) | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 |
| Dividend Per Share(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Earnings Per Share-Unit Curr | 57.07 | 183.11 | 42.84 | 70.80 | 58.46 |
| Earnings Per Share(Adj)-Unit Curr | - | - | - | - | - |
| Book Value | 868.35 | 814.01 | 633.57 | 593.21 | 524.84 |
| Book Value(Adj)-Unit Curr | 868.35 | 814.01 | 633.57 | 593.21 | 524.84 |